# Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer

> **NCT02089854** · PHASE4 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 800 (estimated)

## Conditions studied

- Female Breast Cancer

## Interventions

- **DRUG:** Toremifene; Anastrozole

## Key facts

- **NCT ID:** NCT02089854
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-11
- **Primary completion:** 2019-04
- **Final completion:** —
- **Target enrollment:** 800 (ESTIMATED)
- **Last updated:** 2016-12-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02089854

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02089854, "Adjuvant Endocrine Therapy for Estrogen Receptor-beta Positive Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02089854. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*